Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Small Cell Lung Carcinoma × Topotecan × Clear all

Phase

Phase 2 26 Phase 3 19 Phase 1 12 Phase 1/2 7 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 3 Fallopian Tube Neoplasms 3 Small Cell Lung Carcinoma 1 Retinoblastoma 1 Carcinoma, Ovarian Epithelial 1

Interventions

Drug Therapy 2 sintilimab 1 dinutuximab 1 atezolizumab 1 Topotecan 1 SR 48692 1 Rabeprazole 1 Irinotecan 1 Etoposide 1 Electroporation 1 EC regimen 1 E-3810 1 Cryosurgery 1 Carboplatin 1 Bevacizumab 1 2,2',4,4',5-pentachlorodiphenyl ether 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03098030 2020-12-09

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

United Therapeutics

Phase 2/3 Completed

483 enrolled 19 charts

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡